Santhera Pharmaceuticals (SANN) investor relations material

Company overview and product focus

• Listed on SIX Swiss Exchange with global headquarters near Basel and about 110 employees, planning to remain under 150.

• AGAMREE® (vamorolone) is a unique corticosteroid for Duchenne muscular dystrophy (DMD) with improved safety and efficacy.

• Global rollout underway, with approvals in seven major markets and launches in Germany, Austria, UK, and the US via partners.

• Cash position at end of 2025 was CHF 22.4 million, with an additional USD 40 million upfront from the Nxera licensing deal.

• Cash runway extends to cash-flow break-even expected in Q3 2026.

Market opportunity and expansion

• DMD affects around 300,000 globally, with 90% diagnosed in North America and Europe; 50-75% of patients use steroids.

• The DMD market is valued at over $700 million in North America and over €150 million in Europe.

• AGAMREE is being commercialized directly in Western Europe and through partners in the US, China, and APAC.

• Strategic partnerships include Catalyst (US), Sperogenix (China), and Nxera (Japan, South Korea, Australia, New Zealand).

• Expansion into new territories includes GCC, India, Türkiye, Russia, and ongoing discussions in Latin America.

Product adoption and clinical data

• Over 40% of steroid-using DMD patients in Germany and over 50% in Austria are now on AGAMREE.

• US sales in 2025 reached USD 117 million, exceeding guidance, with 90% of DMD Centers of Excellence using AGAMREE.

• China commercial launch in September 2025, with over 800 patients treated.

• Long-term GUARDIAN study data show durable efficacy and markedly improved safety, including 80% fewer vertebral fractures and normal growth compared to classic corticosteroids.

• AGAMREE maintains efficacy while improving growth and bone health versus standard glucocorticoids.